Arcturus Therapeutics (NASDAQ:ARCT) presented preliminary Phase II data for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase, or OTC, deficiency, while outlining plans to introduce a next-generation delivery platform into the program. OTC deficiency is a urea-cycle disorder in which deficient OTC enzyme activity can lead to toxic ammonia accumulation. Chief Medical Officer Alan Cohen […]